FDA Drug Approval: Biotech Concerns Addressed
- Boston—amid industry apprehension that medicine approvals might face gridlock, the U.S.
- Speaking at a biotech conference Tuesday in Boston, makary stated, "We are hiring scientists at the FDA. I have reinstated people at the FDA." He acknowledged challenges upon...
- Despite the commissioner's assurances regarding the FDA's role in drug approval, the biotech community remains skeptical.
FDA Commissioner Marty Makary addresses biotech firms, reassuring them of continued drug approval processes despite staff cuts initiated by the Trump administration. Despite these assurances, the biotech sector remains wary of potential delays. the FDA’s role in drug approval is under scrutiny, particularly following workforce reductions and the resignation of the top vaccine regulator. Moderna and Solid Biosciences have voiced concerns, highlighting the importance of the FDA’s role in the biotech sector.The agency, however, is implementing initiatives to expedite drug development.News Directory 3 reports that the FDA is launching a program to accelerate drug review times. Discover what’s next in the evolving landscape of biotech regulation.
FDA Chief Reassures Biotech After Staff Cuts, Drug Approval Concerns
Updated June 18, 2025
Boston—amid industry apprehension that medicine approvals might face gridlock, the U.S. Food and Drug Management (FDA) Commissioner marty Makary sought to reassure biotechnology companies that drug approvals would not be delayed. this follows workforce reductions initiated by the Trump administration.
Speaking at a biotech conference Tuesday in Boston, makary stated, ”We are hiring scientists at the FDA. I have reinstated people at the FDA.” He acknowledged challenges upon starting his role in late March, citing staff reductions by Elon Musk’s Department of Government Efficiency. However, Makary asserted that “morale is good and improving,” while also noting “tremendous redundancies” within the agency.
Despite the commissioner’s assurances regarding the FDA’s role in drug approval, the biotech community remains skeptical. Moderna CEO Stéphane Bancel noted on June 11, “There have been a lot of delays across the industry [stemming from the FDA].” Solid Biosciences also cautioned investors in May about potential business impacts due to “delays at the FDA.” These concerns highlight the critical FDA role in the biotech sector.
The Nasdaq biotech index experienced a drop after the abrupt resignation of the FDA’s top vaccine regulator, Peter Marks, on March 28, and is down 3% for the year. Vaccine manufacturers like Moderna have faced particular challenges since President Trump assumed office. Last week,Health and Human Services Secretary Robert F. Kennedy Jr. dismissed the entire top vaccine committee panel responsible for government recommendations.
The panel’s initial meeting with Kennedy’s newly appointed experts is scheduled later this month, raising questions about their stance on the U.S. vaccine schedule.
Makary commented that FDA recommendations for COVID-19 vaccines “are moving closer to the European model,” which he characterized as less aggressive than those in the U.S. He noted that in the U.K., COVID-19 vaccines were recommended for individuals 75 and older and those with high-risk health conditions.
Makary said, “That every 12-year-old healthy child in America needs another 60 doses for the rest of their life — one every year…[That] is not supported with good clinical data for young, healthy people — the repeat booster strategy, in my personal opinion.”
Separately on Tuesday, the FDA announced a program designed to accelerate drug development for specific medicines. The FDA indicated that review times could be reduced from nearly a year to just one to two months. This announcement is expected to be well-received within the biotech industry.
What’s next
The FDA’s efforts to streamline drug approvals and address industry concerns will be closely watched in the coming months, as the biotech sector navigates a changing regulatory landscape.